Lenvatinib mesylateProduct ingredient for Lenvatinib

Name
Lenvatinib mesylate
Drug Entry
Lenvatinib

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.

Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

Accession Number
DBSALT001109
Structure
Synonyms
Lenvatinib mesilate / Lenvatinib mesylate
UNII
3J78384F61
CAS Number
857890-39-2
Weight
Average: 522.96
Monoisotopic: 522.097598
Chemical Formula
C22H23ClN4O7S
InChI Key
HWLFIUUAYLEFCT-UHFFFAOYSA-N
InChI
InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)
IUPAC Name
4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide; methanesulfonic acid
SMILES
CS(O)(=O)=O.COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O
KEGG Drug
D09920
ChemSpider
9412807
ChEBI
85995
ChEMBL
CHEMBL2105704
Wikipedia
Lenvatinib
Predicted Properties
PropertyValueSource
Water Solubility0.00622 mg/mLALOGPS
logP3.03ALOGPS
logP2.52Chemaxon
logS-4.8ALOGPS
pKa (Strongest Acidic)12.37Chemaxon
pKa (Strongest Basic)5.4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area115.57 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity112.21 m3·mol-1Chemaxon
Polarizability42.29 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon